找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Diagnoses Without Names; Challenges for Medic Michael D. Lockshin,Mary K. Crow,Medha Barbhaiya Book 2022 Springer Nature Switzerland AG 202

[復(fù)制鏈接]
樓主: Clinton
11#
發(fā)表于 2025-3-23 13:25:59 | 只看該作者
Ever-Evolving Disease Classification Criteria for Clinical Trials and Studies: The Case of Systemic ue patient, classification and classification criteria are used to describe populations for clinical trials and studies and to create somewhat homogeneous, reproducible, and understood populations for clinical research. The development of classification criteria with high sensitivity and specificity
12#
發(fā)表于 2025-3-23 16:05:05 | 只看該作者
13#
發(fā)表于 2025-3-23 19:28:52 | 只看該作者
When the Illness Has No Name: Focus on Clinical Trials in Systemic Lupus Erythematosusrials, especially those with oversight by regulatory agencies, are pure, they are not. Systemic lupus erythematosus (SLE) clinical trials suffer from some of the same issues that plague everyday clinical life. Does everyone in a clinical trial truly have SLE? Is the activity score declared in the ca
14#
發(fā)表于 2025-3-23 22:32:15 | 只看該作者
15#
發(fā)表于 2025-3-24 06:16:10 | 只看該作者
Managing and Tolerating Diagnostic Uncertaintyfor managing diagnostic uncertainty, however, this pursuit is inadequate. Diagnostic knowledge takes time to acquire, and diagnostic uncertainty is not completely curable. Furthermore, diagnostic uncertainty elicits negative psychological responses that need to be palliated, as well as positive resp
16#
發(fā)表于 2025-3-24 09:50:41 | 只看該作者
17#
發(fā)表于 2025-3-24 11:21:14 | 只看該作者
In the Box or Out of the Boxtudies in well-defined population. Inclusion and exclusion criteria may be the most important aspect of a clinical study or trial. Lumping or splitting determines which patients can ultimately use a risk stratification algorithm or a therapy. Both processes are valid; studies must be more transparent about how they have lumped or split.
18#
發(fā)表于 2025-3-24 17:54:25 | 只看該作者
19#
發(fā)表于 2025-3-24 21:32:47 | 只看該作者
20#
發(fā)表于 2025-3-25 02:09:14 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-21 01:18
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
潞城市| 大新县| 监利县| 永吉县| 灵寿县| 千阳县| 九江县| 德令哈市| 伊春市| 泰来县| 扎囊县| 姚安县| 博兴县| 锡林浩特市| 东安县| 灌阳县| 锦州市| 洛隆县| 阿图什市| 开远市| 嘉禾县| 淮安市| 定结县| 马关县| 城口县| 九龙坡区| 延安市| 奉节县| 云安县| 连江县| 礼泉县| 墨竹工卡县| 通海县| 乐亭县| 荣成市| 会理县| 杭锦旗| 顺义区| 紫阳县| 施秉县| 乌恰县|